Trial Profile
A first-in-human Phase I trial assessing safety, tolerability and immunomodulatory effects of Foralumab in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Foralumab (Primary)
- Indications Amyotrophic lateral sclerosis; Multiple sclerosis; Neurodegenerative disorders
- Focus Adverse reactions; First in man; Proof of concept
- 23 Nov 2022 According to a Tiziana Life Sciences media release, data from this study published in Frontiers in Immunology
- 23 Nov 2022 Results published in the Tiziana Life Sciences Media Release
- 26 May 2021 Results published in the Tiziana Life Sciences Media Release.